vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and APPFOLIO INC (APPF). Click either name above to swap in a different company.
APPFOLIO INC is the larger business by last-quarter revenue ($262.2M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). APPFOLIO INC runs the higher net margin — 16.2% vs 11.1%, a 5.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 20.4%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 15.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
AppFolio, Inc. is an American company founded in 2006 that offers software-as-a-service (SaaS) applications and services to the real estate industry.
ANIP vs APPF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $262.2M |
| Net Profit | $27.5M | $42.4M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 19.4% |
| Net Margin | 11.1% | 16.2% |
| Revenue YoY | 29.6% | 20.4% |
| Net Profit YoY | 367.5% | 35.2% |
| EPS (diluted) | $1.14 | $1.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $262.2M | ||
| Q4 25 | $247.1M | $248.2M | ||
| Q3 25 | $227.8M | $249.4M | ||
| Q2 25 | $211.4M | $235.6M | ||
| Q1 25 | $197.1M | $217.7M | ||
| Q4 24 | $190.6M | $203.7M | ||
| Q3 24 | $148.3M | $205.7M | ||
| Q2 24 | $138.0M | $197.4M |
| Q1 26 | — | $42.4M | ||
| Q4 25 | $27.5M | $39.9M | ||
| Q3 25 | $26.6M | $33.6M | ||
| Q2 25 | $8.5M | $36.0M | ||
| Q1 25 | $15.7M | $31.4M | ||
| Q4 24 | $-10.3M | $102.7M | ||
| Q3 24 | $-24.2M | $33.0M | ||
| Q2 24 | $-2.3M | $29.7M |
| Q1 26 | — | 19.4% | ||
| Q4 25 | 14.1% | 17.6% | ||
| Q3 25 | 15.9% | 14.1% | ||
| Q2 25 | 6.6% | 17.2% | ||
| Q1 25 | 13.3% | 15.5% | ||
| Q4 24 | -2.3% | 11.3% | ||
| Q3 24 | -13.8% | 20.7% | ||
| Q2 24 | 3.7% | 18.3% |
| Q1 26 | — | 16.2% | ||
| Q4 25 | 11.1% | 16.1% | ||
| Q3 25 | 11.7% | 13.5% | ||
| Q2 25 | 4.0% | 15.3% | ||
| Q1 25 | 8.0% | 14.4% | ||
| Q4 24 | -5.4% | 50.4% | ||
| Q3 24 | -16.3% | 16.0% | ||
| Q2 24 | -1.7% | 15.0% |
| Q1 26 | — | $1.18 | ||
| Q4 25 | $1.14 | $1.10 | ||
| Q3 25 | $1.13 | $0.93 | ||
| Q2 25 | $0.36 | $0.99 | ||
| Q1 25 | $0.69 | $0.86 | ||
| Q4 24 | $-0.45 | $2.79 | ||
| Q3 24 | $-1.27 | $0.90 | ||
| Q2 24 | $-0.14 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $147.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $470.2M |
| Total Assets | $1.4B | $580.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $147.4M | ||
| Q4 25 | $285.6M | $107.0M | ||
| Q3 25 | $262.6M | $76.1M | ||
| Q2 25 | $217.8M | $73.5M | ||
| Q1 25 | $149.8M | $56.9M | ||
| Q4 24 | $144.9M | $42.5M | ||
| Q3 24 | $145.0M | $62.4M | ||
| Q2 24 | $240.1M | $59.6M |
| Q1 26 | — | $470.2M | ||
| Q4 25 | $540.7M | $542.6M | ||
| Q3 25 | $505.8M | $498.9M | ||
| Q2 25 | $436.8M | $455.6M | ||
| Q1 25 | $418.6M | $462.1M | ||
| Q4 24 | $403.7M | $519.3M | ||
| Q3 24 | $405.9M | $412.8M | ||
| Q2 24 | $455.8M | $371.4M |
| Q1 26 | — | $580.6M | ||
| Q4 25 | $1.4B | $689.0M | ||
| Q3 25 | $1.4B | $640.5M | ||
| Q2 25 | $1.3B | $567.4M | ||
| Q1 25 | $1.3B | $564.7M | ||
| Q4 24 | $1.3B | $626.7M | ||
| Q3 24 | $1.3B | $523.3M | ||
| Q2 24 | $920.8M | $479.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $34.3M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 0.81× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $34.3M | ||
| Q4 25 | $30.4M | $65.0M | ||
| Q3 25 | $44.1M | $86.0M | ||
| Q2 25 | $75.8M | $52.6M | ||
| Q1 25 | $35.0M | $38.5M | ||
| Q4 24 | $15.9M | $36.6M | ||
| Q3 24 | $12.5M | $57.8M | ||
| Q2 24 | $17.4M | $50.9M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $63.7M | ||
| Q3 25 | $38.0M | $84.7M | ||
| Q2 25 | $71.8M | $52.4M | ||
| Q1 25 | $32.5M | $38.2M | ||
| Q4 24 | $13.5M | $36.4M | ||
| Q3 24 | $7.7M | $57.4M | ||
| Q2 24 | $13.0M | $50.8M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 25.7% | ||
| Q3 25 | 16.7% | 34.0% | ||
| Q2 25 | 34.0% | 22.2% | ||
| Q1 25 | 16.5% | 17.6% | ||
| Q4 24 | 7.1% | 17.9% | ||
| Q3 24 | 5.2% | 27.9% | ||
| Q2 24 | 9.4% | 25.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.5% | ||
| Q3 25 | 2.7% | 0.5% | ||
| Q2 25 | 1.9% | 0.1% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.2% | 0.2% | ||
| Q2 24 | 3.2% | 0.0% |
| Q1 26 | — | 0.81× | ||
| Q4 25 | 1.10× | 1.63× | ||
| Q3 25 | 1.66× | 2.56× | ||
| Q2 25 | 8.87× | 1.46× | ||
| Q1 25 | 2.23× | 1.23× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | 1.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
APPF
| Value Added Services | $201.4M | 77% |
| Subscription Services | $58.2M | 22% |
